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Abstract
Background: Tuberous sclerosis (TSC) is a hamartoma syndrome in which renal and lung tumors
cause the greatest morbidity. Loss of either TSC1 or TSC2 in TSC hamartomas leads to activation
of mTORC1 and suppression of AKT. Recent studies indicate that inhibition of mTORC1 with
RAD001 (everolimus) leads to rebound activation of AKT, which could protect tumors from drug-
induced cell death. Here we examine the potential benefit of inhibition of both mTOR and AKT
signaling in a mouse model of TSC, using a dual pan class I PI3K/mTOR catalytic small molecule
inhibitor NVP-BEZ235.
Results: Using ENU to enhance Tsc2+- kidney tumor development, both RAD001 (10 mg/kg PO 5
d/week) and NVP-BEZ235 (45 mg/kg PO QD) had equivalent effects in suppressing tumor
development during a 4 week treatment period, with a 99% reduction in tumor cell mass. Marked
reduction in activation of mTORC1, induction of cell cycle arrest, and absence of apoptotic cell
death was seen in mice treated with either drug. However, when either was discontinued, there
was prompt recovery of tumor growth, with extensive proliferation.
Conclusion:  Both mTORC1 blockade alone and combined PI3K-mTOR blockade lead to
suppression of tumor development but not tumor elimination in this TSC model.
Background
Tuberous sclerosis (TSC) is an autosomal dominant
tumor suppressor gene syndrome, in which involvement
of the brain, kidneys, and lungs cause the greatest clinical
problems [1]. Seizures, mental retardation, developmen-
tal delay, and autistic features are common during child-
hood in these patients, and in many patients these clinical
issues persist into adulthood. However, after puberty,
additional major clinical problems in TSC are the progres-
sive development of renal angiomyolipoma (AML) and
pulmonary lymphangioleiomyomatosis (LAM) [2,3].
Both of these lesions are made up of unusual smooth
muscle-like and other cells which express both melano-
somal markers and VEGF-D. Although progression of
these lesions is quite variable from patient to patient, loss
of renal function due to either progressive growth of AMLs
and/or conversion into a malignant renal tumor is seen in
about 5% of TSC patients. Pulmonary LAM is seen nearly
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exclusively in female TSC patients, and leads to progres-
sive respiratory limitation and failure also in about 5%.
LAM is also seen independent of the TSC syndrome, typi-
cally in a more severe and progressive form.
Tsc mouse models have been generated consisting of both
knock out and conditional alleles of Tsc1 and Tsc2 [4,5].
None of these replicates the typical features of AML/LAM,
though renal epithelial tumors are a consistent develop-
ment in both Tsc1+- and Tsc2+- mice, which progress over a
period of many months from pure cysts to papillary ade-
nomas to renal carcinoma.
The TSC1 and TSC2 proteins form a tight complex, which
functions in a conserved signaling pathway to regulate the
kinase activity of mTORC1, through regulation of the
state of GTP loading of Rheb [6,7]. Several studies have
shown the benefit of rapamycin and other mTORC1
inhibitors in the treatment and prevention of renal
tumors in Tsc mouse models [8,9].
Loss of TSC1/TSC2 in TSC hamartomas leads to both acti-
vation of mTORC1, as well as feedback inhibition of AKT,
through downregulation of IRS and PDGFR expression
and other mechanisms [10,11]. This has led to specula-
tion that treatment of TSC hamartomas with mTORC1
inhibitors might lead to restoration of AKT activation, as
seen in vitro with treatment of TSC1/TSC2 null cells, and
in some patients with malignant disease [12], which may
compromise clinical benefit. Here, we explore the poten-
tial benefit of the mTORC1 inhibitor RAD001
(everolimus) in comparison to a dual pan-class I PI3K/
mTOR catalytic inhibitor NVP-BEZ-235 [13] in the ther-
apy of Tsc2 mouse kidney tumors.
Methods
Mouse procedures
Tsc2+- mice, originally generated in this laboratory [4],
were serially crossed with C57BL/6J mice for over 5 gener-
ations, and were then mated with pure 129S1/SvImJ mice
to generate Tsc2+-  mixed strain C57BL/6J:129S1/SvImJ
mice. These mixed strain mice were used in all experi-
ments. All procedures were carried out in accordance with
the Guide for the Humane Use and Care of Laboratory
Animals, and the study was approved by the Animal Care
and Use Committee of Children's Hospital, Boston. N-
ethyl-N-nitrosourea (ENU, Sigma-Aldrich) was prepared
in ethanol at 200 mg/ml, diluted in phosphate-citrate
buffer, and administered by intraperitoneal (IP) injection
at 60 mg/kg.
Standard histology and tumor assessment
Standard histology sections were prepared from mouse
kidneys after 10% formalin fixation and cutting into five
1–2 mm sections. Both gross and microscopic kidney
pathology was read by a blinded observer (KP) and scored
according to a modification of a formula used previously
[14]. The kidney tumor score for kidney cystadenomas
was determined as a summed score for all lesions in a kid-
ney, scoring each individual tumor grossly as follows: 1
for tumors <1 mm; 2 for 1 to 1.5 mm; 5 for 1.5 to 2 mm;
10 for > 2 mm. Microscopic kidney tumor scores were
determined similarly, except that the score for each lesion
was multiplied by 2 if the tumor had a papillary compo-
nent, and by 4 if it was a solid adenoma. The percent cel-
lularity of cystadenomas was determined as the percent of
the tumor that contained proliferating cells as opposed to
cyst cavity; pure cysts had a score of 0% cellularity while
solid adenomas had a score of 100% cellularity. Compar-
ison between sets of mice for tumor measurements were
made using the non-parametric Kruskal-Wallis test.
Antibodies and immunohistochemistry
Antibodies used were: pS6(S235/236) clone 91B2, active
caspase-3 clone 5A1 from Cell Signaling Technology, Bed-
ford, MA; pS6(S240) clone DAK-S6-240 M7300,
pAKT(S473) clone 14–5, Ki-67 clone TEC-3 M7249, and
pMAPK(pTpY202/4) clone 24-2-2 from DAKO S/A, Den-
mark; PCNA (PC10) from Santa Cruz Biotechnology. For
immunohistochemistry, kidneys were rapidly removed,
sliced in thirds and fixed overnight at 4°C in 10% forma-
lin. Paraffin sections were cut and stained by the immu-
noperoxidase technique, following standard methods of
deparaffinization, antigen retrieval using Dako Target
Retrieval solution, DAB incubation, and counterstaining
with hematoxylin. The percent Ki-67 or PCNA labeling, or
percent of cells expressing active caspase 3, within a lesion
was determined by direct counting of at least 300 cells by
a blinded observer (IM).
Drug handling and administration
RAD001 was provided by Novartis in a proprietary vehicle
at 20 mg/ml. Prior to each administration, RAD001 was
diluted in water to 0.5–2 mg/ml, and was given at 10 mg/
kg by gavage every day 5 days per week. NVP-BEZ235 was
provided by Novartis as a powder, and was mixed in 10%
1-Methyl-2-pyrrolidone and 90% PEG-300 at 8 mg/ml. It
was prepared fresh prior to each administration, and was
given at either 15 mg/kg or 45 mg/kg by gavage every day.
In the first treatment cohort, mice were treated with pla-
cebo (10% 1-Methyl-2-pyrrolidone and 90% PEG-300)
by gavage 5 days per week. This was not done in subse-
quent cohorts.
Results
ENU acts as a carcinogen to enhance renal tumor growth 
in Tsc2+- mice
Kidney tumor growth in Tsc2+- mice follows a variable
though predictable pattern with an effect of strain on
tumor severity [4], (unpublished). In most strains, age 12Molecular Cancer 2009, 8:38 http://www.molecular-cancer.com/content/8/1/38
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months is the earliest at which significant kidney tumors
are seen. To accelerate the rate of development of renal
tumors, we treated Tsc2+- mice with ENU, an alkylating
agent which causes point mutations. We explored the
effects of administration of a single IP dose of ENU at sev-
eral different times during mouse development, evaluat-
ing tumor severity at 6 months of age [see Additional file
1]. To minimize effects of genetic background, we studied
mice that were heterozygous for the C57BL/6J and 129S1/
SvImJ strains. We found that ENU given at ages from E13
to P21 (administered to the pregnant dam in the first
case) was effective at increasing the incidence and severity
of kidney cystadenomas in the Tsc2+- mice, as assessed by
gross evaluation [see Additional file 1]. ENU treatment at
these ages in wild type mice of the same strain mix led to
rare renal tumors (e.g. only one < 1 mm tumor in 10 mice
treated with ENU at P9) at age 6 months. Microscopic
assessment of the ENU-treated Tsc2+- mice confirmed this
enhancement in tumor development (data not shown).
Administration of ENU at any of P9, E19, or E13 appeared
to have similar outcomes, with nearly identical kidney
tumor scores (see Methods for details) [see Additional file
1]. We chose to use P9 administration for simplicity in the
following studies.
Evaluation of RAD001 alone and in combination with 
NVP-BEZ235 in the ENU-accelerated Tsc2+- kidney tumor 
model
We explored the potential benefit of mTORC1 inhibition
with RAD001 in the ENU-accelerated Tsc2+- kidney tumor
model. RAD001 was highly effective in reducing the gross
tumor score, microscopic tumor score, and percent solid
tumor (Figure 1A–C) in these mice, after a 4-week period
of treatment at 10 mg PO QD 5 days out of seven each
week, beginning at age 20 weeks. Combining the reduc-
tion in overall tumor size with reduction in cellularity
indicates that there was an approximate 99% reduction in
tumor development. In addition, the residual lesions seen
in the RAD001-treated mice generally had a flattened epi-
thelium, in contrast to the enlarged columnar-like epithe-
lial cells seen in untreated mice [see Additional file 2]. We
also examined the acute effects of treatment with RAD001
in this model. Tumor analysis 3–5 days after initiation of
therapy demonstrated that RAD001 markedly reduced
expression of pS6(S240) and pS6(S235/236), consistent
with mTORC1 blockade [see Additional file 3]. In addi-
tion, the Ki-67 labeling index in the short-term treated
tumors was reduced from an average of 6% to an average
of 1% (Figure 1D) [see Additional file 3]. However, there
was no indication of induction of apoptosis or necrosis in
the tumors, as expression of activated caspase-3 was very
low in the treated tumors (0–1% cells) similar to that seen
in untreated tumors [see Additional file 4A] (in contrast to
control nude mouse tumor xenograft samples, data not
shown). In addition, there was no consistent effect on
MAPK signaling, as assessed by staining for
pMAPK(pTpY202/4) (data not shown), in the treated
tumors. However, RAD001 treatment caused an increase
in pAKT(S473) levels in the tumors, which were very low
in tumors from untreated mice [see Additional file 5].
Total S6 and AKT protein levels were similar in normal
kidney and in the tumors, and did not appear to change
significantly with treatment with either compound [see
Additional file 5]. Four week treatment with RAD001 also
did not lead to significant apoptosis in these kidney
tumors, though it did cause continued suppression of pro-
liferation [see Additional file 4].
Simultaneously, we evaluated the potential benefit of
combining RAD001 inhibition of mTORC1 with PI3K-
mTOR inhibition using NVP-BEZ235. NVP-BEZ235 was
also given alone (without RAD001), as a control, and at
relatively low dosage (15 mg/kg PO QD) appeared to
have significant therapeutic effect in the ENU-treated
Tsc2+- mice (Figure 1A–C). Improvement was seen in
both gross and microscopic kidney tumor scores, with a
more modest change in tumor cellularity. These observa-
tions are probably due to the activity of NVP-BEZ235 as a
direct mTOR inhibitor, affecting both mTORC1 and
mTORC2, in addition to its PI3K inhibition activity [13].
Consistent with this effect, NVP-BEZ235 inhibits phos-
phorylation of S6 at the S235/236 sites in Tsc2 null
murine embryo fibroblast cell lines at 10–100 nM, and
has a potent anti-proliferative effect on these cells with an
IC50 of 3 nM [15].
Comparison of RAD001 and NVP-BEZ235 as therapy for 
the ENU-accelerated Tsc2+- kidney tumor model
Since NVP-BEZ235 had effects in inhibiting mTOR, and at
low doses could reduce tumor development in this
model, we treated a cohort of ENU-treated Tsc2+- mice
with NVP-BEZ235 at full dosage, 45 mg/kg PO QD [13],
and compared outcome with RAD001 treatment. NVP-
BEZ235 had similar effects to RAD001 in reducing both
gross and microscopic kidney tumor scores by about 80%,
with most residual lesions being simple cysts (Figure 2A–
C). Tumor cellularity also appeared reduced in general,
though the presence of a single solid adenoma in an NVP-
BEZ235-treated mouse ran against this trend. Tumor cell
size was reduced in NVP-BEZ235-treated mice [see Addi-
tional file 2]. In short term as well as 4 week treatment tri-
als, NVP-BEZ235 stopped cell proliferation, with
complete loss of Ki-67 or PCNA staining in the treated
tumors (Figure 2D) [see Additional files 3, 4]. Similar to
RAD001, NVP-BEZ235 did not appear to cause apoptosis
in the tumor cells [see Additional file 4A]. pS6(S240) and
pS6(S235/236) expression was markedly reduced in the 5
day NVP-BEZ235-treated mouse kidney tumors [see Addi-
tional file 3]. pAKT(S473) levels were low in the NVP-
BEZ235-treated mouse tumors, similar to untreated mice,
but in contrast to RAD001-treated mice [see Additional
file 5]. There was no statistically significant differenceMolecular Cancer 2009, 8:38 http://www.molecular-cancer.com/content/8/1/38
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between the kidney tumor scores or cellularity of the
tumors seen in these mice after RAD001 or NVP-BEZ235
treatment.
Comparison of RAD001 and NVP-BEZ235 as therapy for 
the ENU-accelerated Tsc2+- kidney tumor model with 
long-term follow-up
Since RAD001 and NVP-BEZ235 had similar effects in
arresting the growth of the kidney tumor epithelial cells
during a four week period of treatment, we asked whether
one or the other treatment might be more beneficial in
terms of lasting effects on tumor growth in mice treated
transiently. To explore this question, mice were treated
with either drug for a period of 4 weeks, age 20 – 24
weeks, and then were taken off drug for 8 weeks and sac-
rificed for examination. Kidney tumors in mice treated
with either drug showed robust growth with development
of relatively large papillary and solid tumors, and re-
Renal tumor development blocked by administration of RAD001 with or without NVP-BEZ235 in the ENU-treated  +-  model Figure 1
Renal tumor development blocked by administration of RAD001 with or without NVP-BEZ235 in the ENU-
treated Tsc2+- model. A-C. Dot plot analysis of gross kidney tumor score (A), microscopic kidney tumor score (B), and per-
cent cellularity of each lesion (C) in ENU-treated  +- mice at age 24 weeks that received either 1) placebo, 2) RAD001 10 
mg/kg PO 5 d/week, 3) NVP-BEZ235 15 mg/kg PO QD, or 4) a combination of RAD001 and NVP-BEZ235 at the same dosage; 
all for four weeks from age 20 – 24 weeks. A, B: Each dot represents a mouse kidney. C: Each dot represents a mouse kidney 
cystadenoma. A, p < .001; B, p = .03; C, p NS; by Kruskal-Wallis test. D. Dot plot analysis of percent Ki-67+ cells in kidney 
tumors of mice with genotype and treatment as in A-C, but that were analyzed 3 or 5 days after initiation of treatment with 
RAD001 10 mg/kg PO QD at age 24 weeks. Each dot represents a mouse kidney cystadenoma. p < .0001 Kruskal-Wallis test.Molecular Cancer 2009, 8:38 http://www.molecular-cancer.com/content/8/1/38
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expression of PCNA [see Additional file 4B]. Gross tumor
scores were significantly reduced in mice treated with
either drug in comparison to never-treated mice; however,
there was no significant difference in microscopic tumor
scores or percent cellularity (Figure 3) [see Additional file
2]. Gross and microscopic kidney tumor scores, percent
papillary and solid tumors, and general histologic charac-
teristics of the tumors in these mice did not differ accord-
ing to the drug treatment received. Thus, both RAD001
and NVP-BEZ235 had major effects on tumor growth dur-
ing the treatment period, but resumption of brisk tumor
growth occurred upon cessation of treatment.
Renal tumor development blocked by administration of either RAD001 or NVP-BEZ235 in the ENU-treated  +- model Figure 2
Renal tumor development blocked by administration of either RAD001 or NVP-BEZ235 in the ENU-treated 
Tsc2+- model. A-C. Dot plot analysis of gross kidney tumor score (A), microscopic kidney tumor score (B), and percent cellu-
larity of each lesion (C) in ENU-treated  +- mice at age 24 weeks that received either 1) no treatment, 2) RAD001 10 mg/kg 
PO 5 d/week, or 3) NVP-BEZ235 45 mg/kg PO QD; all for four weeks from age 20 – 24 weeks. A, B: Each dot represents a 
mouse kidney. C: Each dot represents a mouse kidney cystadenoma. A, p < .001; B, p = .03; C, p NS; by Kruskal-Wallis test. D. 
Dot plot analysis of percent Ki-67+ cells in kidney tumors of mice with genotype and treatment as in A-C, but that were ana-
lyzed 3 or 5 days after initiation of treatment with NVP-BEZ235 45 mg/kg PO QD at age 24 weeks. Each dot represents a 
mouse kidney cystadenoma. p < .0001 Kruskal-Wallis test.Molecular Cancer 2009, 8:38 http://www.molecular-cancer.com/content/8/1/38
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Discussion
Tuberous sclerosis affects an estimated 40,000 individuals
in the United States, and about 10% of these individuals
are projected to sustain significant morbidity and often
mortality due to development and progression of renal
AML, pulmonary LAM, other less common tumors of the
retroperitoneum (lymphangioma) or liver (angiomyol-
ipoma), PEComas arising in various sites, and neuroendo-
crine tumors [1]. The major understanding of the function
of the TSC1/TSC2 protein complex as a critical regulator
of the Rheb GTPase and thereby mTORC1 activity in
recent years has led to considerable enthusiasm about the
Renal tumor recurrence in mice treated with either RAD001 or NVP-BEZ235 8 weeks after coming off drug Figure 3
Renal tumor recurrence in mice treated with either RAD001 or NVP-BEZ235 8 weeks after coming off drug. 
A-C. Dot plot analysis of gross kidney tumor score (A), microscopic kidney tumor score (B), and percent cellularity of each 
lesion (C) in ENU-treated  +- mice at age 32 weeks that received either 1) no treatment, 2) RAD001 10 mg/kg PO 5 d/
week, or 3) NVP-BEZ235 45 mg/kg PO QD; all for four weeks from age 20 – 24 weeks. A, B: Each dot represents a mouse kid-
ney. C: Each dot represents a mouse kidney cystadenoma. A, p = .002; B and C, p NS; by Kruskal-Wallis test.Molecular Cancer 2009, 8:38 http://www.molecular-cancer.com/content/8/1/38
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potential efficiency of rapamycin and other mTORC1
inhibitors as therapy for these TSC tumors [7]. Two phase
I-II trials of rapamycin therapy for TSC renal AML and/or
pulmonary LAM have been published [16,17]. The larger
trial reported that among the 80% patients staying on
drug, those with renal AML responded to rapamycin with
an average 47% reduction in tumor volume. Although
this was gratifying, the reduction in size was largely
reversed, returning to 86% of starting volume on average,
when follow-up for a year off drug was performed. Since
no biopsies were performed in these patients, there is a
lack of understanding of precisely what happened to these
tumors both when the patients were treated and when the
drug was stopped.
Here we demonstrate, similar to previous reports using
rapamycin [8,9], that RAD001 is highly effective in sup-
pressing the growth of Tsc mouse kidney cystadenomas,
with an average 99% reduction in tumor cell burden in
this ENU-accelerated Tsc2+- model. In addition, we dem-
onstrate that there is very effective suppression of cell
growth within these lesions, as assessed by reduction in
Ki-67 positivity, with a lack of apoptosis or tumor cell
death. Pathway inhibition with reduction in markers of
mTORC1 activation, pS6(S240) and pS6(S235/236), was
also seen, consistent with the expected mechanism of
action of the drug. However, marked tumor regrowth
occurred by 8 weeks after discontinuation of RAD001,
though some persistent reduction in overall tumor bur-
den could be appreciated in comparison to never-treated
mice (Figure 3A). We find these observations to be in
striking parallel to those made in AML patients, taking
into account the markedly different growth rates of renal
AMLs in patients in comparison to renal cystadenomas in
this model. They suggest that rapamycin/RAD001 has a
cytostatic effect, effectively blocking the growth of the
renal AMLs and likely reducing cell size, but without
tumor cell death. Upon drug removal, there is regrowth of
tumors. Further, they suggest the possibility that contin-
ued mTORC1 inhibition may have benefit for maintain-
ing growth suppression of these tumors.
It is well-recognized that the mTOR signaling pathway in
which TSC1/TSC2 participate is more complex than first
thought, with a number of feedback inhibitory effects of
loss of the TSC protein complex on AKT activation
[10,11,18]. In addition, the related mTORC2 complex has
a major if not sole role in phosphorylating and enhancing
activation of AKT at Serine 473 [19]. In most tumor cell
lines, including Tsc1 null and Tsc2 null MEF cell lines,
treatment with rapamycin or RAD001 leads to phosphor-
ylation of AKT at the S473 site, and increased activation
[11,12,20]. There has been concern that this effect could
mitigate any positive treatment effect of mTORC1 inhibi-
tors on tumor growth. Here we assessed the possibility
that combined PI3K-AKT-mTOR blockade with NVP-
BEZ235 could lead to a better therapeutic outcome in this
Tsc2+- kidney tumor model. We found that the short-term
effects of NVP-BEZ235 were similar to those of RAD001
with a major reduction in cell proliferation, lack of apop-
tosis or cell death, and reduction in markers of mTORC1
activation. NVP-BEZ235 has PI3K inhibitory activity at
low nM levels in vitro for all PI3Kα including mutant
forms, and has been shown to reduce pAKT(S473) levels
in xenograft models [13]. As expected, pAKT(S473) levels
were low in the kidney tumors from untreated Tsc2+- mice,
and were increased by treatment with RAD001, but not
NVP-BEZ235. In addition, in vitro studies demonstrate
that in full serum pAKT(S473) levels are low in Tsc2 null
MEF lines, are increased somewhat with RAD001 treat-
ment, and reduced somewhat by NVP-BEZ235 treatment
[15]. Despite the short-term effects of treatment with
NVP-BEZ235, we found that in both the 4 week course of
drug, and 4-week course with 8-week off drug follow-up,
that RAD001 and NVP-BEZ235 had indistinguishable
effects, with marked regrowth of tumor following treat-
ment cessation. Thus, these observations suggest that the
reactivation of mTORC1 in TSC-related neoplasms that
might occur with rapamycin/RAD001 treatment has no
significant clinical effect, at least in this Tsc model tumor.
Conclusion
We have conducted a trial of the pure mTORC1 inhibitor
RAD001 and the combined PI3K/mTOR inhibitor NVP-
BEZ235 in a mouse model of TSC in which the mice
develop renal cystadenomas. Both drugs were highly
effective at tumor growth suppression, and there was no
difference between combined PI3K-mTOR blockade in
comparison to mTORC1 inhibition alone. When treat-
ment was discontinued, rapid tumor regrowth was seen
after each drug. In this model, both drugs appear to have
a primarily cytostatic effect.
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Kruskall-Wallis test.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-38-S1.pdf]
Additional file 2
Morphology of RAD001- and NVP-BEZ235-treated Tsc2+- kidney 
lesions. Multiple tumor H&E stained images are shown from ENU-
treated Tsc2+- kidneys. All scale bars are 100 microns. Each image is 
taken from a different mouse. Light black lines delineate tumor (T) or cyst 
(C) vs. normal kidney (N). Row A- Mice of age 24 weeks; inset shows 
hyperplastic columnar-type epithelium lining the cyst; Row B- Mice of age 
24 weeks that were treated with RAD001 5 days per week, from age 20–
24 weeks; inset shows flat epithelium lining the cyst: Row C- Mice of age 
24 weeks that were treated with NVP-BEZ235 45 mg/kg daily from age 
20–24 weeks; Row D- Mice of age 32 weeks; Row E- Mice of age 32 weeks 
that were treated with RAD001 5 days per week, from age 20–24 weeks; 
Row F- Mice of age 32 weeks that were treated with NVP-BEZ235 45 mg/
kg daily from age 20–24 weeks.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-38-S2.pdf]
Additional file 3
Signaling pathway and growth analysis by IHC in Tsc2+- mice. A sin-
gle representative image is shown for untreated mice (top row), mice 
treated for 5 days with RAD001 10 mg/kg PO (middle row), and mice 
treated for 5 days with NVP-BEZ235 45 mg/kg PO (bottom row). All 
mice were ENU-treated Tsc2+- mice of age 24 weeks. Columns are: 
pS6(S240), pS6(S235/236), Ki-67. Adjacent sections from each tumor 
are shown. All images are taken at 100×. Note that the third row has a 
background pink/orange shade, which is present in all cells on this section, 
and distinct from the dark brown stain seen in the top row.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-38-S3.pdf]
Additional file 4
Apoptosis and proliferation in Tsc2+- mice. A. The percent cleaved cas-
pase 3 positive cells are shown for Tsc2+- mice, treated for either 5 days 
('SHORT') or for 4 weeks ('CHRONIC'). Each dot represents a different 
renal cystadenoma for which the percent positive cells was determined by 
a blinded observer (IM). B. The percent PCNA positive cells are shown for 
Tsc2+- mice, treated with either RAD001 or NVP-BEZ235, or treated 
with these drugs and then taken off drug for 8 weeks ('ON/OFF'). Each 
dot represents a different renal cystadenoma.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-38-S4.pdf]
Additional file 5
Signaling pathway analysis by IHC in Tsc2+-mice. A single representa-
tive image is shown for untreated mice (top row), mice treated for 5 days 
with RAD001 10 mg/kg PO (middle row), and mice treated for 5 days 
with NVP-BEZ235 45 mg/kg PO (bottom row). All mice were ENU-
treated Tsc2+- mice of age 24 weeks. Columns are: pS6(S235/236); S6 
(total); pAKT(S473); AKT (total). Adjacent sections from each tumor are 
shown. All images are taken at 100×.
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